Quote | Adagio Therapeutics Inc. (NASDAQ:ADGI)
Last: | $4.64 |
---|---|
Change Percent: | -0.43% |
Open: | $4.62 |
Close: | $4.64 |
High: | $4.74 |
Low: | $4.4 |
Volume: | 535,536 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Adagio Therapeutics Inc. (NASDAQ:ADGI)
Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administration Reimbursement through Medicare/Medicaid represents approximately 50% of covered lives in target population WALTHAM, Mass., April ...
WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Exe...
Message Board Posts | Adagio Therapeutics Inc. (NASDAQ:ADGI)
Subject | By | Source | When |
---|---|---|---|
Lets gooooo$$$ | INFINITI | investorshub | 03/30/2022 3:34:33 PM |
Let her run geez | INFINITI | investorshub | 03/30/2022 3:06:31 PM |
Going to burst mark it $$$ | INFINITI | investorshub | 03/30/2022 2:52:43 PM |
On watch | Penny chatter | investorshub | 03/30/2022 2:50:23 PM |
Possible | Penny chatter | investorshub | 03/30/2022 2:49:59 PM |
News, Short Squeeze, Breakout and More Instantly...
Adagio Therapeutics Inc. Company Name:
ADGI Stock Symbol:
NASDAQ Market:
Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224) defines reimbursement for product administration Reimbursement through Medicare/Medicaid represents approximately 50% of covered lives in target population WALTHAM, Mass., April ...
WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, today announced that the company’s Board of Directors has appointed Jeremy Gowler as Interim Chief Exe...
PEMGARDA now commercially available in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain adults and adolescents with moderate-to-severe immune compromise Based on anticipated net product revenue and continued optimization of operational expenses, company expects to end 2...